Home
Search results “Holden comprehensive cancer center dr oncology”
The University of Iowa Holden Comprehensive Cancer Center
 
03:06
George Weiner, M.D., director of the Holden Comprehensive Cancer Center, John Buatti, M.D., deputy director of clinical care at the Holden Comprehensive Cancer Center, Rachel Maassen, M.D., obstetrics and gynecology, and Dr. Mohammed Milhem, M.D., medical oncology, talk about the advantages of receiving treatment at the Holden Comprehensive Cancer Center.
Views: 223 GreaterCROpen
Comprehensive Cancer Care: Integrative Oncology with Daniel Vicario MD and Paul J. Mills
 
27:12
(Visit: http://www.uctv.tv/) Medical oncologist Daniel Vicario, co-founder of the San Diego Cancer Center, talks about his pioneering research in integrating Western medicine with ancient healing techniques as he develops comprehensive treatment plans for his patients. In this conversation with Paul J. Mills of UC San Diego, Dr. Vicario gives examples of treatments that have led to a decrease in symptoms, fewer doctor visits and a higher quality of life for those who are responsive to holistic cancer care. Recorded on 03/22/2017. Series: "The UC Wellbeing Channel " [5/2017] [Show ID: 32223]
Holden Comprehensive Cancer Center - University of Iowa Hospitals and Clinics
 
03:15
A new cancer clinic and infusion suite at UI Hospitals and Clinics brings Holden Comprehensive Cancer Center physicians and researchers together and creates a more comfortable and efficient atmosphere for patients.
The Expertise within Holden Comprehensive Cancer Center - George Weiner, MD
 
03:27
George Weiner, MD, Director of Holden Comprehensive Cancer Center at the University of Iowa, explains how the three branches of Holden—cancer care, research, and education—set it apart from other cancer centers as a truly comprehensive center, with the expertise to reduce the burden of cancer for Iowans and beyond.
Cancer Teams = M.O.G.s (Multidisciplinary Oncology Groups) - Mo Milhem, MBBS
 
03:31
Cancer patients at Holden Comprehensive Cancer Center at the University of Iowa (https://www.uihealthcare.org/cancer/) benefit from teams made up of cancer specialists and researchers who discuss the best treatment options for every patient, all while using the latest research findings. Mohammed Milhem, MBBS, medical oncologist, explains. For more information on Multidisciplinary Oncology Groups at UI Hospitals and Clinics, visit http://www.uihealthcare.org/multidisciplinary-oncology-groups/ or call (800) 777-8442.
Radiation Therapy for Leiomyosarcoma - Anusha Kalbasi, MD | UCLA Cancer Care
 
36:24
UCLA radiation oncologist Anusha Kalbasi, MD, talks about radiation therapy options to treat leiomyosarcoma. Learn more about the UCLA Sarcoma Program ➨ https://www.uclahealth.org/sarcoma/
Views: 705 UCLA Health
Dr. Finn on Role of Lenvatinib in HCC Treatment Paradigm
 
02:56
Richard Finn, MD, professor of clinical medicine in the Division of Hematology and Oncology, director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles, discusses the role lenvatinib (Lenvima) in the treatment paradigm for advanced hepatocellular carcinoma.
Views: 52 OncLiveTV
Jonsson Comprehensive Cancer Center
 
04:14
UCLA's Jonsson Comprehensive Cancer Center is among the nation's top 10 cancer centers (US News & World Report). The JCCC has established an international reputation for pioneering the development of revolutionary targeted therapies.
Views: 1622 UCLAJCCC
Dr. Hurvitz on HER2-Targeted Therapies in Breast Cancer
 
02:01
Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses HER2-targeted therapies for the treatment of breast cancer.
Views: 82 OncLiveTV
Melanoma - Mo Milhem, MBBS
 
03:50
Medical oncologist Mohammed Milhem, MD, of Holden Comprehensive Cancer Center at the University of Iowa, discusses melanoma: how it starts, spreads, and is diagnosed. (https://www.uihealthcare.org/melanoma/) For more information about melanoma, visit https://www.uihealthcare.org/melanoma/ or call (800) 777-8442.
George J. Weiner, MD: Big Ten Cancer Research Consortium
 
01:01
George J. Weiner, MD, director of the Holden Comprehensive Cancer Center at the University of Iowa discusses the importance of multi-institutional collaboration in cancer research. http://www.bigtencrc.org
Dr. Ganz on 2018 Giant of Cancer Care in Supportive/Palliative/Geriatric Cancer
 
01:34
Patricia A. Ganz, MD, medical oncologist, David Geffen School of Medicine and Jonsson Comprehensive Cancer Center-Supportive Care/Palliative/Geriatric, UCLA, discusses her career milestones and being named a 2018 Giant of Cancer Care® in Supportive/Palliative/Geriatric Cancer.
Views: 5 OncLiveTV
Dr. Garon on Sequencing of Agents for Advanced Lung Cancer
 
01:59
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing challenges for patients with advanced lung cancer.
Views: 64 OncLiveTV
Dr. Mohammed Milhem discusses melanoma in Iowa
 
02:04
Dr. Mohammed Milhem of The University of Iowa's Holden Comprehensive Cancer Center discusses melanoma in the state of Iowa and the fact that the highest risk group for developing the most dangerous form of skin cancer is a 50-year-old man.
Views: 726 GreaterCROpen
Dr. Finn on Cyclin-Dependent Kinases and the Treatment of Cancer
 
02:04
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer. For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Views: 205 Targeted Oncology
Comprehensive Cancer Support Program: A Team Approach
 
03:55
At the UNC Lineberger Comprehensive Cancer Support Program, we operate outstanding clinical and educational programs for cancer patients and their caregivers, as well as a world-class training and research site for health care professionals who work with cancer patients. We aim to provide compassionate and effective care for all North Carolina cancer patients and their families. Many cancer patients describe diagnosis, treatment and survivorship as a journey - sometimes one that comes with confusing maps and directions or without signposts and guidebooks. That's why the UNC Lineberger Comprehensive Cancer Center and the N.C. Cancer Hospital created the Comprehensive Cancer Support Program (CCSP). For more information, please visit UNCLineberger.org/ccsp
Views: 987 UNC Lineberger
Leiomyosarcoma: Personalized Sarcoma Therapy - Fritz C. Eilber, MD | UCLA Cancer Care
 
48:34
Dr. Fritz C. Eilber talks about the the history of sarcoma and Leiomyosarcoma treatment at UCLA. Dr. Eliber is Director of the UCLA Sarcoma Clinical/Translational Research Program within the Jonsson Comprehensive Cancer Center and the Sarcoma Program Area within the Institute of Molecular Medicine. Learn more ➨ https://www.uclahealth.org/sarcoma/
Views: 1444 UCLA Health
Chandrikha Chandrasekharan, MBBS
 
01:51
Chandrikha is a medical oncologist in the Holden Comprehensive Cancer Center, at University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Sequencing Agents for the Treatment of Patients With Melanoma
 
00:49
Antoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses how to appropriately sequence therapies for patients with melanoma.
Views: 61 Targeted Oncology
Dr. Antoni Ribas Discusses the Giants of Cancer Care Program
 
00:36
Antoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses the honor of being recognized as a 2015 Giant of Cancer Care in Melanoma and provides an overview of the oncology awards program.
Views: 194 OncLiveTV
Dr. Hurvitz on Biosimilars in Breast Cancer
 
01:46
Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses biosimilars in breast cancer.
Views: 79 OncLiveTV
Welcome to Radiation Therapy at University of Iowa Hospitals and Clinics
 
12:28
Take a tour of University of Iowa Radiation Oncology to learn what happens during radiation treatment for cancer. This is a detailed education video to better prepare patients for radiation therapy mixed with patient stories. For more information, please call 319-356-2253 or visit us at http://www.uihealthcare.org/cancer
UCLA's Jonsson Comprehensive Cancer Center Fights Cancer
 
05:10
UCLA's Jonsson Comprehensive Cancer Center has over 235 physicians and scientists who have played crucial roles in the development of FDA approved cancer therapies for patients world-wide. The JCCC provides the latest in experimental cancer treatments and hundreds of clinical trials.
Views: 757 UCLAJCCC
What Does It Mean to Be a Comprehensive Cancer Center?
 
01:16
The University of Maryland Marlene and Stewart Greenebaum Cancer Center recently earned the National Cancer Institutes highest designation as a comprehensive cancer center. Learn more: http://umm.edu/programs/cancer/about-us/nci-ccc-designation
Views: 650 UMMCVideos
Surgical Management of Uterine Leiomyosarcoma - Joshua G. Cohen, MD | UCLA Cancer Care
 
28:46
Dr. Joshua G. Cohen talks about diagnosis and treatment options for gynecological cancers including uterine leiomyosarcoma. Learn more about the Sarcoma Program at UCLA ➨ https://www.uclahealth.org/sarcoma/
Views: 1058 UCLA Health
Sarcoma: Developing Drugs for Rare Disease - Arun Singh, MD | UCLA Cancer Care
 
29:11
UCLA oncologist Arun Singh, MD gives an overview of sarcomas and leiomyosarcomas, rare tumors that arise in the bones, and connective tissue such as fat and muscle. Learn more ➨ https://www.uclahealth.org/sarcoma/
Views: 809 UCLA Health
Dr. McCloskey on Postoperative Radiation in Patients With Breast Cancer
 
01:20
Susan A. McCloskey, MD, MSHS, assistant professor of radiation oncology, University of California Los Angeles (UCLA) Medical Center, Jonsson Comprehensive Cancer Center, discusses the evolution of postoperative radiation in patients with breast cancer.
Views: 31 OncLiveTV
Dr. Hurvitz on Novel Emerging Agents in HER2+ Breast Cancer
 
01:55
Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses novel agents that are emerging in the HER2-positive breast cancer space. Hurvitz shared this insight in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.
Views: 284 OncLiveTV
Dr. Glaspy on Immunogenicity in Ovarian Cancer
 
01:22
John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles (UCLA) School of Medicine, discusses immunogenicity in ovarian cancer.
Views: 63 OncLiveTV
Dr. Antoni Ribas on Combining Vemurafenib and Ipilimumab for Metastatic Melanoma
 
00:58
Antoni Ribas, MD, Department of Medicine, Division of Hematology-Oncology; Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA), describes a phase I/II trial that plans to combine the BRAF inhibitor vemurafenib (Zelboraf) and the cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor ipilimumab (Yervoy) for patients with BRAF V600-mutated metastatic melanoma. For more melanoma and skin cancer resources, visit http://www.onclive.com/specialty/melanoma
Views: 612 OncLiveTV
Sequencing Immunotherapy in Advanced-Stage Lung Cancer
 
03:34
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer. There had been a lot of debate about the timing of when patients should receive a PD-1 inhibitor, Garon explains. Results of the KEYNOTE-024 study ended that debate when they showed patients with high levels of staining for PD-L1 were more likely to have an improvement in progression-free survival (PFS) if they received pembrolizumab (Keytruda) over chemotherapy. Additionally, there was a survival advantage seen in patients who received the PD-1 inhibitor as their initial therapy. There is now a debate once again with the approval of carboplatin, pemetrexed, and pembrolizumab, based on results of the KEYNOTE-021 study. Garon says the main take-home message is that these are all options. He has been reluctant to use all these therapies together in his own practice, due to the increase in toxicity, but he is eager to see results of large, phase III studies using all of these agents.
Views: 112 Targeted Oncology
George Weiner, MD
 
01:35
George Weiner is a hematologist and oncologist at University of Iowa Hospitals and Clinics, Iowa City, Iowa. He also serves as the Director, Holden Comprehensive Cancer Center,a matrix cancer center coordinating all cancer activities across the University of Iowa regardless of departmental, collegiate, or organizational boundaries.
Dr. Hurvitz on the Impact of Biosimilars
 
01:38
Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the impact of biosimilars in the treatment of patients with breast cancer.
Views: 45 OncLiveTV
Dr. Finn on Regorafenib for the Treatment for Patients With HCC
 
16:35
Richard Finn, assistant professor of Medicine at the Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology at UCLA Jonsson Comprehensive Cancer Center, discusses regorafenib (Stivarga) for the treatment of patients with hepatocelluar carcinoma.
Views: 611 OncLiveTV
Dr. Richard Finn on PD 0332991 Plus Letrozole in ER-Positive Breast Cancer
 
01:05
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, describes results from a phase II study that examined PD 0332991, an oral selective inhibitor of cyclin-dependent kinase 4/6, in combination with letrozole as a first-line treatment for postmenopausal women with metastatic ER-positive breast cancer. To view more coverage from SABCS, visit http://www.onclive.com/conference-coverage/sabcs-2012
Views: 776 OncLiveTV
Dr. Ganz on Survivorship Care Plans for Patients with Cancer
 
02:01
Patricia Ganz, MD, UCLA Jonsson Comprehensive Cancer Center, discusses how to better integrate survivorship plans for patients with cancer.
Views: 87 OncLiveTV
Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma
 
00:54
Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma.
Views: 105 Targeted Oncology
Dr. Garon on Antiangiogenic Agents in Lung Cancer
 
01:25
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.
Views: 38 OncLiveTV
"Introduction to the Clinical and Translational Science Institute
 
30:37
BioBasics Layman Seminar: Research Administrators Campus Committee Presents Steven Dubinett, MD Director, Clinical and Translational Science Institute, Associate Vice Chancellor for Research, Senior Associate Dean for Translational Research, Professor & Chief, Division of Pulmonary & Critical Care Medicine, UCLA Department of Medicine Dr. Steven M. Dubinett is Chief of the Division of Pulmonary and Critical Care Medicine and Director of the Jonsson Comprehensive Cancer Center (JCCC) Lung Cancer Research Program. He has extensive experience in translational investigation, academic administration, mentorship and peer review. He is jointly appointed as Professor in three departments: Medicine, Pathology and Laboratory Medicine, and Molecular and Medical Pharmacology. At UCLA since 1988, he is a member of the Institute of Molecular Medicine, the Molecular Biology Institute, and the California NanoSystems Institute. Building on original discoveries relevant to inflammation in the pathogenesis of lung cancer, he has developed a translational research program which now utilizes these laboratory-based discoveries in the translational research and clinical environment. Dr. Dubinett has received continuous peer-reviewed federal funding for translational lung cancer research for more than 20 years. As a member of NCI.s Translational Research Working Group, Dr. Dubinett participated in designing pathways to clinical goals: developmental pathways that characterize the transformation of scientific discoveries into new clinical modalities for oncology. Dr. Dubinett serves as the Director for Biomarker Development for the American College of Surgeons Oncology Group and oversees biospecimen utilization in the context of clinical trials. He currently serves as the Chair of the Research Evaluation Panel for biospecimen utilization for the American College of Radiology Imaging Network/National Lung Screening Trial (ACRIN/NLST). He also is a member of the FDA Cellular, Tissue & Gene Therapies Advisory Committee.
U-M Comprehensive Cancer Center Community Outreach
 
02:33
The University of Michigan Comprehensive Cancer Center's Community Outreach Program is committed to providing reliable health information, tailored programs and special events to educate the community about cancer prevention, screening, and early diagnosis, and, increase awareness of, and trust in research conducted at UMCCC.
Views: 117 Michigan Medicine
Mo Milhem, MBBS
 
01:37
Mo Milhem is a hematologist and oncologist at University of Iowa Hospitals and Clinics, Iowa City, Iowa
CO-1686 - An Irreversible, Highly Selective TKI of Mutations of EGFR
 
02:48
Dr. Jonathan Goldman from UCLA Jonsson Comprehensive Cancer Center talks about CO1686, filmed at IASLC in February 2014. Oncology.TV would like to acknowledge CancerGrace.org and the Lungevity Foundation in their support for the filming.
Views: 250 Oncology.TV
CAR T-cell Therapy for Pediatric Cancer - Satiro de Oliveira, MD | UCLA Cancer Services
 
31:47
Join UCLA pediatric oncologist Satiro De Oliveira, MD, for a discussion about CAR T-cell therapy for pediatric patients, including indications, plan of care, side effects, risks and benefits. Learn more: https://www.uclahealth.org/car-t-cell-therapy #UCLAMDChat
Views: 241 UCLA Health
How Cancer Spreads (Metastasis) - Michael Henry, PhD
 
03:47
Metastasis is the spread of cancer from one site to another and is responsible for the vast majority of deaths from cancer. Holden Comprehensive Cancer Center at the University of Iowa (http://www.uihealthcare.org/holden/) is focused on researching the nature of cancer cells, with a particular emphasis on the process of metastasis. In this video Michael Henry, PhD, describes the metastasis of prostate cancer and how this process affects treatment options. (http://www.uihealthcare.org/what-is-cancer/) For more information about our cancer treatment visit http://www.uihealthcare.org/cancer/ or call 800-777-8442.
Dr. Finn on the Inhibition of CDK 4/6 in Breast Cancer
 
01:53
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, explains the preclinical trial and rationale that led to the phase II trial of PD 0332991, which he presented at SABCS. For more targeted therapy resources: http://targetedhc.com/
Views: 181 Targeted Oncology
NFF | Epigenetics Research with Dr. John Glaspy
 
10:28
Spend a few minutes with Dr. John Glaspy, professor of medicine at the Jonsson Comprehensive Cancer Center (JCCC) of the University of California, Los Angeles (UCLA) School of Medicine. Dr. Glaspy discusses Epigenetics Research.
Views: 761 Noreen Fraser
Conversations: Let's Talk About Bladder Cancer - Spotlight on BCG
 
25:49
"Conversations: Let's Talk About Bladder Cancer -- Spotlight on BCG" is the latest episode hosted by BCAN President and Co-Founder Diane Zipursky Quale. In this most recent show she talks about Bacille Calmette-Guerin (BCG) treatment for bladder cancer with two experts in the field: - Dr. Donald Lamm, BCG Oncology President - Dr. Michael O'Donnell, Professor of Urology, Holden Comprehensive Cancer Center, University of Iowa Click here for more information: http://www.bcan.org/ This video was supported by a generous grant from Photocure (http://www.photocure.com).
Dr. Hurvitz on the FDA Approval Process for Biosimilars
 
01:55
Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses when to use a biosimilar over the originator drug.
Views: 81 OncLiveTV
Dr. Richard Finn on the Difficulties of Treating Liver Cancer
 
02:18
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the difficulties of treating liver cancer. For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Views: 68 Targeted Oncology
Dr. Richard Finn on the Future of Palbociclib in Breast Cancer
 
01:34
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, describes the potential impact of the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (PD-0332991) in the treatment of patients with ER-positive metastatic breast cancer. For more information on palbociclib, visit http://www.onclive.com/conference-coverage/sabcs-2012/New-Agent-Significantly-Improves-Progression-Free-Survival-in-Patients-with-Advanced-ER-Breast-Cancer
Views: 371 OncLiveTV